Glaxo Venture's Lofty Goal in HIV: Eclipse Gilead as Top Player
Sanofi Plots Cancer Comeback With First New Drug in Seven Years
Drugmakers Risk Wasting Big Money on Brexit, U.K. Lobbyist Says
Treasury Department Hasn't Responded to Cohen Probe Request
Merck Is Said to Prepare for Supply Blackout in Brexit Planning
Europe's Drug Agency Warns of Bigger Staff Losses in Brexit Move
Lightning Strike Causes Flight Delays at London Stansted Airport
Glaxo Cuts Jobs in Finance, Adds in Cancer in Hunt for Drugs
Novartis works to repair tarnished image after Cohen deal.
Trump Lawyer Cohen Dangled Policy Help, Ex-Novartis Chief Says
Novartis Says General Counsel to Retire After Cohen Payments
Novartis CEO Is Said to Dial Up 5,000 Managers After Cohen Furor
Novartis “made a mistake” in signing up lawyer Michael Cohen to give it some insight Trump’s health-care plans.
Novartis was drawn into Mueller’s probe of suspected Russian meddling in the U.S. presidential election.
Glaxo's Advair Is the $100 Billion Asthma Drug That Won't Die
Sanofi sees “huge potential” from the field of blood disorders after completing the acquisition of Bioverativ.
Too Many Drugmakers Chase Same Targets, Sanofi's Zerhouni Says
Gates Sees Promise in Microbiome Studies, New Vaccine Technology
Sanofi Finance Chief to Leave After Almost a Decade at Drugmaker
Glaxo, Novartis Join $4 Billion Gates-Led Push to Fight Malaria
After $1 Million Drug Flop, UniQure Seeks Gene-Therapy Revival